Grade @ or greater adverse events occurring in @ % or more of patients in either treatment group were ascites ( @ -LSB- @ % -RSB- of @ patients treated with ramucirumab vs @ -LSB- @ % -RSB- of @ patients treated with placebo ) , hypertension ( @ -LSB- @ % -RSB- vs ten -LSB- @ % -RSB- ) , asthenia ( @ -LSB- @ % -RSB- vs five -LSB- @ % -RSB- ) , malignant neoplasm progression ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , increased aspartate aminotransferase concentration ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , thrombocytopenia ( @ -LSB- @ % -RSB- vs one -LSB- < @ % -RSB- ) , hyperbilirubinaemia ( three -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , and increased blood bilirubin ( five -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .